Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma
November 27, 2013
- CHMP Recommends Approval of Otsuka’s Delamanid for Treatment of MDR-TB
November 27, 2013
- IFN-Free Hepatitis C Drugs Could Hit Pharmacy Shelves in 2014, New Option for Elderly Patients
November 26, 2013
- Alfresa Pharma Gets Additional Indication for Anafranil
November 26, 2013
- Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan
November 26, 2013
- GSK’s Paxil Granted Japan’s 1st PTSD Indication
November 26, 2013
- Japan’s 1st Acetaminophen IV Injection Now Available
November 26, 2013
- Chugai’s Avastin Approved for Ovarian Cancer Treatment
November 25, 2013
- AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs
November 25, 2013
- Preminent Generics of 30-Plus Firms Likely to Carry “Losarhyd” Brand; Unified Trade Names Logged for 4 More Combination Generics
November 25, 2013
- Kyowa Kirin Launches New PIII Trial for Istradefylline
November 25, 2013
- ASKA Pharmaceutical Plans to Launch Generic Version of Takeda’s Leuplin, Aims for 20% Market Share
November 25, 2013
- Once-Monthly Injectable Abilify Maintena Approved in Europe: Otsuka
November 25, 2013
- Domestic Ethical Drug Market Estimated to Reach 9,617.7 Billion Yen in 2020: Fuji Keizai
November 22, 2013
- Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases
November 22, 2013
- Mid-sized Foreign Drug Makers Eying Full-scale Entry into Japanese Market Encouraged by Favorable Changes in Market Environment; Marketing Systems May Be Key to Success
November 22, 2013
- Japan Diovan Sales Down 15.7% in July-September: IMS
November 22, 2013
- Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda
November 21, 2013
- Novartis’ Compliance Advisory Board Holds 1st Meeting amid Diovan Fuss
November 21, 2013
- JT’s Anti-HIV Agent Elvitegravir Wins European Regulatory Approval
November 21, 2013
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…